Pano Therapeutics

Pano Therapeutics is a biotechnology company dedicated to developing first-in-class small molecule inhibitors targeting mitochondrial metabolism. The company specifically focuses on the Mitochondrial Pyruvate Carrier (MPC), a protein complex that facilitates the entry of pyruvate into the mitochondria. By inhibiting this carrier, Pano aims to redirect cellular metabolism to treat chronic metabolic conditions such as nonalcoholic steatohepatitis (NASH) and type 2 diabetes. Their research is based on foundational discoveries regarding the role of MPC in liver glucose production and insulin sensitivity. The company is currently advancing its lead candidate through pre-clinical development to address significant unmet needs in metabolic health.